| Inducing apoptosis |
1336 |
| Cell membrane disintegration |
526 |
| Apoptosis inducing |
523 |
| Not available |
440 |
| Target and destroy tumor cell membranes |
424 |
| Cell membrane damage |
299 |
| Membrane disruption |
218 |
| Inducing membrane permeabilization |
144 |
| Cyclization enhances apoptosis via lysosomes |
135 |
| Cell membrane disruption |
134 |
| Penetration and disruption of the membrane |
117 |
| Selective membrane perforation prevents resistance. |
117 |
| Disruption of cell membranes |
115 |
| Membrane disruption mechanism |
98 |
| Cell membrane penetration |
70 |
| Inducing mitochondria-dependent apoptosis |
63 |
| Inhibition of cell signalling |
57 |
| Physical membrane disruption |
50 |
| Dissipate ion gradients; Induce osmotic lysis; Membrane damage |
50 |
| Disruption of cell membrane |
48 |
| Apoptosis; Necrosis |
41 |
| Induce apoptosis |
41 |
| Membrane permeabilization via lysine substitution |
39 |
| Cell entry, DNA damage, apoptosis. |
36 |
| Inducing mitochondrial apoptosis |
36 |
| Charge-optimized membranolysis induces apoptosis. |
35 |
| Apoptosis |
33 |
| Immunomodulatory activity |
31 |
| Penetration and disruption of the membranes |
28 |
| Stapled peptide enhances helical apoptosis |
28 |
| Dendrimerization enhances stability, selectivity, anticancer efficacy |
27 |
| Cell membrane disintegration; Apoptosis |
26 |
| 5c inhibits cancer via kinase blockade |
26 |
| Macrocyclic peptides disrupt cancer growth |
26 |
| Disintegration of cell membrane |
25 |
| Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death |
25 |
| Apoptotic inducing |
25 |
| Enhanced cationicity/hydrophobicity increases cytotoxicity |
25 |
| Proline-substituted AMP triggers mitochondrial apoptosis |
24 |
| Cell proliferation inhibition; Cell penetration; Apoptosis |
24 |
| Targeting the MIEN1 signaling pathway |
24 |
| Induction of apoptosis; Disruption of cell membrane |
24 |
| Anti-proliferative action |
23 |
| Membrane disruption triggers apoptosis |
23 |
| Membrane disruptive mode of action |
22 |
| Peptides target phosphatidylserine, trigger apoptosis |
21 |
| Pore formation at the cytoplasmic membrane |
21 |
| Charge–hydrophobicity balance drives apoptosis |
21 |
| Destabilization of membranes |
20 |
| Gonearrestide induces G1 cell-cycle arrest |
20 |
| Cytotoxic effects |
20 |
| Necrosis; Cell membrane rupture |
19 |
| Induction of apoptosis |
19 |
| Cytotoxic |
19 |
| Disruption of cancer cell membrane integrity |
18 |
| Necrosis or apoptosis |
18 |
| Anti-proliferative effects |
18 |
| Cell membrane penetrating |
17 |
| Helical peptides disrupt cancer membranes |
17 |
| Cell growth inhibition and apoptosis |
17 |
| Membrane disruption induces apoptotic signaling. |
16 |
| Immune response regulation |
16 |
| Cell membrane Permeabilization |
16 |
| Ile/Leu residues crucially mediate cytolysis |
16 |
| Membrane permeabilization |
16 |
| Cell apoptosis |
14 |
| Permeabilization of the lipid membrane of the target cells |
14 |
| Necrosis; Apoptosis |
14 |
| Cell cycle arrest or apoptosis of cells |
13 |
| Membranolytic mechanism |
13 |
| Dual anticancer and BBB-blockade. |
13 |
| Apoptosis induction, Bax/p53/caspase activation |
13 |
| Immune response to tumor cell recognition |
13 |
| GLUT1-mediated uptake enhances cytotoxicity |
12 |
| Modulates membrane interactions |
12 |
| Mitochondrial mediated apoptosis |
12 |
| Plasma memberane pore formation |
12 |
| Membrane disruption induces cancer apoptosis |
12 |
| PCNA interference disrupts DNA repair. |
12 |
| Apoptosis, drug-resistance reversal, tumor suppression |
12 |
| Destroy plasma membrane |
12 |
| Motif-driven membrane insertion triggers cytotoxicity |
12 |
| LPA reduction suppresses tumor growth |
11 |
| Membrane-disruption |
11 |
| Cell membrane disintegration; Regulation of immune response; Apoptosis |
11 |
| Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis |
11 |
| Apoptosis inducing; Anti-proliferative activity |
11 |
| Membrane disruption and cell lysis |
11 |
| Cell-cycle arrest induces apoptosis |
10 |
| Immunomodulatory properties |
10 |
| Disruption of cancer membrane integrity |
10 |
| Necrosis |
10 |
| Membrane disruption and cationic enhancement |
10 |
| Antiangiogenis; Immune regulation |
10 |
| Dissipate ion gradients;Induce osmotic lysis; Membrane damage |
10 |
| Membrane perforation |
10 |
| Anti-angiogenesis |
9 |
| Mitochondrial apoptosis via p53 activation |
9 |
| Membrane lysis |
9 |
| Anti-proliferative effect |
9 |
| Disrupting the integrity of cell membrane |
9 |
| h-APN receptor–mediated apoptosis induction. |
9 |
| Antiproliferative effect |
9 |
| Mitochondrial apoptosis via p53 activation. |
8 |
| FOXM1 inhibitor |
8 |
| Necrosis; Immune regulation |
8 |
| Cu²⁺-mediated membrane lipid oxidation |
8 |
| Disruption of either cancer or bacterial cell membrane integrity |
8 |
| α-helix enhances antimicrobial, anticancer activity |
8 |
| Inhibition of the cell proliferation |
8 |
| Disruption of membrane |
7 |
| Immune modulation |
7 |
| SFP induces S-phase cell-cycle arrest |
7 |
| Immunoregulation |
7 |
| Apoptosis inducing; Penetration of the cell membrane |
6 |
| Cell proliferation inhibition |
6 |
| Tubulin depolymerization |
6 |
| p53 stabilization and LDHA inhibition |
6 |
| Cell membrane permeabilisation |
6 |
| Anti-proliferative activity |
6 |
| Apoptosis induction and immune activation |
6 |
| Perturbation of the cell membrane |
6 |
| Selective binding, membrane disruption, apoptosis |
6 |
| Necrosis; Antiangiogenesis |
6 |
| Plasma membrane perturbations |
6 |
| Antiangiogenesis |
6 |
| Cell proliferation inhibition; Apoptosis inducing |
6 |
| Immunomodulatory mechanisms |
6 |
| Cell membrane disruption; Cell apoptosis |
6 |
| Prevents C/EBPβ dimerization, induces degradation |
6 |
| Inhibits FOXM1 transcriptional activities |
6 |
| Disruption of the membrane |
6 |
| Membrane disruption induces necrotic death |
6 |
| Necrotic activity via cell
membrane lysis and apoptotic activity through disrupting
mitochondrial membrane |
6 |
| Cell necrosis; Inhibiting processes of protein synthesis; Damaging the mitochondrial membrane |
5 |
| Peptide 327 blocks Eps8–EGFR |
5 |
| Induce apoptosis and cell cycle arrest |
5 |
| Membrane disruption triggers dual apoptosis |
5 |
| Membrane disruption triggers ROS-mediated apoptosis |
5 |
| Immunogenic response regulation |
5 |
| Mitochondrial targeting, VDAC1-HKII dissociation |
5 |
| Destroying the cell membranes |
5 |
| R2PLx induces caspase-dependent apoptosis |
5 |
| Positive charge–driven membrane disruption apoptosis |
5 |
| Inhibit COX-2 enzyme |
5 |
| F-actin modulation induces necrotic death. |
5 |
| Regulation of immune response |
5 |
| Membrane damage; Apoptotic cell death; Necrosis |
5 |
| pH-triggered release, membrane lysis, immunogenic death |
4 |
| Cell penetration |
4 |
| Membrane disruption by pore-formation or by permeating the membrane and acting on intracellular targets |
4 |
| Induce G1 arrest and increased apoptotic cell populations at the sub-G1 phase |
4 |
| Cell penetration without toxic accumulation |
4 |
| Induces apoptosis and necrosis |
4 |
| NKp44-pep8 inhibits PCNA function |
4 |
| Apoptotic death |
4 |
| Induce cell apoptosis; Targets on the cell membranes and caused membrane lysis |
4 |
| Pore formation on cell membrane |
4 |
| Membrane disruption mediates selective cytotoxicity. |
4 |
| Plasma membrane perturbation; Necrosis |
4 |
| ROS induction, mitochondria-mediated apoptosis. |
4 |
| Apoptosis inducing; Necrotic cell death |
4 |
| Apoptosis and thus cell nucleus fragmentation |
4 |
| Antiproliferative activity |
4 |
| Mitochondrial targeting induces apoptosis |
4 |
| Disrupting cancer cell membranes |
4 |
| Promote apoptosis; Inhibits the proliferation and migration of lung cancer cells both in vitro and in vivo |
4 |
| EGFR-targeted defensin induces mitochondrial apoptosis |
4 |
| Cause cell membrane permeability; Induce necrotic death |
4 |
| IL13Rα2 blockade inhibits cancer metastasis |
4 |
| Membrane penetration, cytoplasmic leakage |
4 |
| Disrupts XIAP-survivin, induces apoptosis/necroptosis |
4 |
| Cell swelling and rupture of the plasma membrane |
4 |
| Disrupt cell membrane structure |
4 |
| Membrane lysis via pore formation |
4 |
| p53-mediated Bax/Bcl-2 apoptosis activation |
4 |
| Membrane disruption via cationic interaction |
3 |
| Cell membrane degradation |
3 |
| Necrosis; Anti-angiogenesis |
3 |
| Disulfide-stabilized peptide disrupts pathogens |
3 |
| ABCB1 inhibition, MDR reversal, sensitization |
3 |
| Cell metatstasis inhibition |
3 |
| Peptide-induced cell death |
3 |
| Cellular necrosis |
3 |
| Integrin-targeting, α-helix mediated lysis |
3 |
| Apoptosis induction |
3 |
| Disrupts transcription |
3 |
| Disrupt the structure and function of cell membranes |
3 |
| Membrane disruption, α-helix mediated |
3 |
| Membrane disruption, necroptosis, limited apoptosis |
3 |
| Regulation of immune response; Apoptosis inducing |
3 |
| Membrane disruption induces cell death |
3 |
| Immune regulation |
3 |
| Apoptosis induction and immune modulation. |
3 |
| Cytotoxicity |
3 |
| Cytotoxic; Anti-proliferative; Apoptosis |
3 |
| Disruption of cancer cell membranes; Apoptosis |
3 |
| Cell invasion |
3 |
| p53-mediated apoptosis |
3 |
| DNA damage and apoptosis induction |
3 |
| Necrosis; Membrane disruption |
3 |
| Apoptosis; Immunomodulatory activity |
3 |
| Cyclotides induce cytotoxicity, inhibit migration |
3 |
| Apoptosis inducing; Anti-proliferative |
3 |
| Mitochondrial dysfunction, caspase-dependent apoptosis |
3 |
| Bothropoidin inhibits breast cancer progression |
3 |
| Apoptosis via integrin-Akt suppression |
3 |
| Membrane damage as swelling; Breakage or blebbing |
3 |
| Cytoplasmic membrane disintegration |
2 |
| Blocker of chloride channels and can inhibit the migration of glioma cells |
2 |
| Immunomodulating agent |
2 |
| Necrotic cell death |
2 |
| Reactive Oxygen Species and Apoptotic Pathways |
2 |
| Membrane disruption, apoptosis, selective cytotoxicity |
2 |
| ERK-mediated apoptosis and mitochondrial disruption |
2 |
| Temporin-1OLa disrupts bacterial membranes |
2 |
| Interact with the lipids of the plasma membrane |
2 |
| ROS, p53, mitochondrial apoptosis activation |
2 |
| Inducing cell membrane damage |
2 |
| Disruption of membrane permeability |
2 |
| Can affect tumor cells directly in an autocrine manner |
2 |
| Apoptosis induction, p53-mediated cell cycle arrest |
2 |
| Membrane disintegration due to pore-forming or carpet-like mechanisms of action |
2 |
| Apoptosis; Cell proliferation |
2 |
| Membrane rupture |
2 |
| Membrane disruption, selective cancer cytotoxicity |
2 |
| Induce apoptotic and necrotic cell deaths |
2 |
| Tumor angiogenesis inhibition |
2 |
| Triggers the apoptotic cascade |
2 |
| Sp1 suppression, apoptosis, cell-cycle arrest |
2 |
| Fas activation drives apoptosis/necroptosis |
2 |
| Antinociceptive activity; Membrane disruption |
2 |
| Induce apoptosis; Necrotic activity |
2 |
| Penetrating cell membrane |
2 |
| Disrupt cell membrane structures; Apoptosis |
2 |
| DRS-DU-1 induces selective tumor cytotoxicity |
2 |
| Pyroptosis mediated |
2 |
| Inhibit the migration of prostate cancer cell; Induce apoptosis |
2 |
| Caspase-9 mediated apoptotic death |
2 |
| NF-κB inhibition enhances cisplatin synergy |
2 |
| GPR1 antagonism, PI3K/AKT inhibition |
2 |
| Enhanced binding, mitochondrial dysfunction, apoptosis |
2 |
| Mitochondria-ER targeting, induces multimodal death. |
2 |
| D-FP21 delivers gene, inhibits proliferation |
2 |
| Cell membrane lysis |
2 |
| Reduce cell proliferation and migration |
2 |
| Cell membrane interaction; Necrosis; Apoptosis |
2 |
| GAPDH-like protein disrupts survival |
2 |
| Cytoplasmic membrane permeabilization and DNAspecified-binding |
2 |
| Antiproliferative action |
2 |
| Cytoxicity activity |
2 |
| Acid-triggered membrane disruption apoptosis |
2 |
| Membrane disruption and DNA binding |
2 |
| Disrupts tumor cells |
2 |
| Destroy cell membrane |
2 |
| Through interactions with the plasma membrane |
2 |
| Cell-cycle arrest, apoptosis, autophagy induction |
2 |
| Immunomodulatory activities |
2 |
| Membrane disruption, antifungal, antibacterial, anticancer |
2 |
| Apoptosis; Cell nucleus fragmentation |
1 |
| Membrane destroying mode of action on prokaryotic as well as eukaryotic cells |
1 |
| Apoptotic activity and necroptosis; Plasma membrane permeabilization |
1 |
| Fatty-acid modification enhances peptide apoptosis |
1 |
| Binds anionic phospholipid-rich membranes similar to bacterial membranes and dissolves them like detergents |
1 |
| LfcinB-P13 induces liver cancer apoptosis |
1 |
| Cell membrane destabilization |
1 |
| Rupture cancer cell membranes |
1 |
| Cell membrane permeation |
1 |
| Permeabilizing the membrane |
1 |
| Necrosis; Immunomodulatory activity |
1 |
| Direct pore formation leading to leakage of intracellular components and cell death |
1 |
| Act on the lipid matrix of bacterial cell membranes; Destroying the barrier property and killing the bacteria |
1 |
| E5 inhibits CXCR4–CXCL12 signaling |
1 |
| Formation of a pore or transmembrane channel and ultimately to cell lysis |
1 |
| Pore formation in membrane |
1 |
| Apoptosis via intrinsic (mitochondrial) and extrinsic (death receptor) pathways |
1 |
| TRPV6 inhibition suppresses ovarian tumors |
1 |
| Regulate apoptosis related death receptor/NF-κB signaling pathway |
1 |
| Apoptosis inducing; Intracellular ROS formation |
1 |
| Synergistic autophagic death via AKT inhibition. |
1 |
| Selective cytotoxicity, DNA damage, apoptosis |
1 |
| Pore-formation |
1 |
| Inhibit tumor cell growth |
1 |
| Interference with ionic transport of the osmoregulatory system in epithelium causing cell lysis |
1 |
| Membrane disruption via electrochemical proton gradient |
1 |
| By orientating perpendicularly and inserting into the lipid bilayer of the plasma membrane and so inducing transmembrane pores |
1 |
| Provoking in immune responses |
1 |
| Disruption of electric potential of the cell membrane; Necrosis, Membranolytic activity leading to apoptosis |
1 |
| Causing defects in membrane integrity by the formation of pores |
1 |
| Immune response regulation, apoptosis |
1 |
| Destabilizing the cell membrane |
1 |
| Penetrating the cell membrane |
1 |
| Mediate necrosis |
1 |
| Total regulation of immune defense |
1 |
| Induction of apoptosis; Alteration of mitochondrial permeability |
1 |
| Forms lytic pores in the target cell membrane |
1 |
| Inhibits VEGFR-2 angiogenic signaling |
1 |
| TAK-448 reduces testosterone, inhibits tumor |
1 |
| Cell membrane penetration and lysis |
1 |
| Membrane disintegration |
1 |
| Membrane disruption triggers mitochondrial apoptosis |
1 |
| Inhibits angiogenesis; Apoptosis inducing; Elevation of ROS |
1 |
| L-K6 binds, internalizes, damages nucleus |
1 |
| Targeting PD-L3 |
1 |
| Induce permeabilization of the cytoplasmic membrane |
1 |
| CecropinXJ induces apoptosis in HCC |
1 |
| Disrupting cell membranes; Apoptosis |
1 |
| Inducing G1 arrest |
1 |
| Activating an apoptosis-inducing pathway |
1 |
| Anti-proliferation activity |
1 |
| Permeabilization of lysosomes; Release of Ca2+ from endoplasmic reticulum; Destruction of mitochondrial membrane potential |
1 |
| ROS scavenging induces cancer cell death |
1 |
| Necrotic cell death by destroying cellular membrane structure; Apoptotic cell death |
1 |
| Damages the outer membrane of bacteria |
1 |
| Apoptosis inducing; Elevation of ROS |
1 |
| Permeabilizing bacterial membranes |
1 |
| Targeting PD-L2 |
1 |
| Cell penetration, Mitochondrial dysfunction, Apoptosis pathway activation |
1 |
| Induce necrotic cell death |
1 |
| Inhibit tumor growth and induce specific immune response |
1 |
| NRP1/MDM2 inhibition induces apoptosis |
1 |
| Regulation of immune response; Apoptosis |
1 |
| Disrupt membranes by a pore-forming action |
1 |
| Disintegration of lipid bilayer by forming an ion-channel |
1 |
| Disruption of cellular membranes |
1 |
| Disrupting the ionic homeostasis of the bacterium; Cell lysis |
1 |
| Through the granule-exocytosis pathway may release one or more effector molecules with the capacity to directly kill the intracellular microbial pathogen |
1 |
| Disrupts the acyl chain packing of anionic lipid bilayers, thus cell lysis |
1 |
| Rupture cell membranes |
1 |
| Transmembrane penetration |
1 |
| Regulate caspase-related apoptosis pathways |
1 |
| Damaging the cytoplasmic membrane |
1 |
| Targeting PD-L1 |
1 |
| Destruction of the cell membrane |
1 |
| Selective lysis of cellular membrane |
1 |
| Inhibition of angiogenesis |
1 |
| Membrane destabilization |
1 |
| Cell-penetrating mechanism |
1 |
| Cytoplasmic membrane disruption |
1 |
| MEL-pep disrupts membrane, inhibits P-gp |
1 |
| Membranolytic activity |
1 |
| ASIC inhibition suppresses cancer proliferation |
1 |